Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Virology

• Publication date

  1997-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/jvi.71.9.6816-6822.1997PMID 9261406PMCID PMC191962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.

  1997cited by this paper
• Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration

  1997cited by this paper
• Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products

  1997cited by this paper
• In vivo model of adeno-associated virus vector persistence and rescue

  1996cited by this paper
• Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis

  1996cited by this paper
• Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

  1996cited by this paper
• Effects of Gamma Irradiation on the Transduction of Dividing and Nondividing Cells in Brain and Muscle of Rats by Adeno-Associated Virus Vectors

  1996cited by this paper
• An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.

  1995cited by this paper
• Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung

  1995cited by this paper
• Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells

  1995influential reference
• Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

  1994cited by this paper
• Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence.

  1994cited by this paper
• Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.

  1994cited by this paper
• Adeno-associated virus vectors preferentially transduce cells in S phase.

  1994cited by this paper
• Use of adeno-associated virus as a general transduction vector for mammalian cells.

  1992influential reference
• Adeno-associated virus vectors.

  1992cited by this paper
• Mung bean nuclease cleavage pattern at a polypurine.polypyrimidine sequence upstream from the mouse metallothionein-I gene.

  1991cited by this paper
• A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection.

  1991cited by this paper
• Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein.

  1991cited by this paper
• Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication.

  1989cited by this paper
• Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression

  1989influential reference
• Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein

  1988cited by this paper
• Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli.

  1987cited by this paper
• A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication

  1987cited by this paper
• Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide

  1986cited by this paper
• A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.

  1985cited by this paper
• Complete coding sequence of rat tyrosine hydroxylase mRNA.

  1985cited by this paper
• Structure of simian virus 40-adeno-associated virus recombinant genomes

  1985cited by this paper
• An Escherichia coli recBCsbcBrecF host permits the deletion-resistant propagation of plasmid clones containing the 5'-terminal palindrome of minute virus of mice.

  1985cited by this paper
• Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells.

  1984cited by this paper
• Recombination between simian virus 40 and adeno-associated virus: virion coinfection compared to DNA cotransfection.

  1984cited by this paper
• Nucleotide sequence and organization of the adeno-associated virus 2 genome

  1983cited by this paper
• Cloning of infectious adeno-associated virus genomes in bacterial plasmids.

  1983cited by this paper
• Structure of simian virus 40-phiX174 recombinant genomes isolated from single cells

  1983cited by this paper
• Quantitation of a simian virus 40 nonhomologous recombination pathway

  1983cited by this paper
• High-efficiency ligation and recombination of DNA fragments by vertebrate cells.

  1983cited by this paper
• Structure of mouse metallothionein-I gene and its mRNA

  1981cited by this paper
• Indiscriminate recombination in simian virus 40-infected monkey cells.

  1980cited by this paper
• Defective-interfering particles of the human parvovirus adeno-associated virus.

  1979cited by this paper
• The genome of simian virus 40.

  1978cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper
• A continuous tumor‐cell line from a human lung carcinoma with properties of type II alveolar epithelial cells

  1976cited by this paper
• Selective extraction of polyoma DNA from infected mouse cell cultures.

  1967influential reference

• Safety of in vivo gene therapy in children: mechanisms and management of liver injury.

  2026cites this paper
• Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy

  2026cites this paper
• Unleashing the Power of Biologics: Exploring the Governance and Regulation of Membrane-Based Virus Purification (MVP) Technologies

  2025cites this paper
• Reduced rAAV interference enhances rcAAV detection sensitivity

  2025cites this paper
• Development of cell-based assay for detecting replication-competent adeno-associated virus by qPCR

  2025cites this paper
• Residual DNA impurities in AAV vectors—nature and transcription

  2025cites this paper
• Self-silencing adenovirus enables precise infectious titration of recombinant adeno-associated viral vectors

  2025cites this paper
• Implementation of the quality-by-design concept for an adeno-associated viral vector-based gene therapy

  2025cites this paper
• AAVone: A cost-effective, single-plasmid solution for efficient AAV production with reduced DNA impurities

  2025cites this paper
• Development of Stable Packaging and Producer Cell Lines for the Production of AAV Vectors

  2024cites this paper
• Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation

  2024cites this paper
• Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects

  2024cites this paper
• PCR-based analytics of gene therapies using adeno-associated virus vectors: Considerations for cGMP method development

  2023cites this paper
• Querying Recombination Junctions of Replication-Competent Adeno-Associated Viruses in Gene Therapy Vector Preparations with Single Molecule, Real-Time Sequencing

  2023influential citation
• Enhancing the production of recombinant adeno‐associated virus in synthetic cell lines through systematic characterization

  2023cites this paper
• Exploring the Comprehensive Kozak Sequence Landscape for AAV Production in Sf9 System

  2023cites this paper
• The downstream bioprocess toolbox for therapeutic viral vectors.

  2023cites this paper
• Recombinase-Aided Amplification Combined with Lateral Flow (LF-RAA) Assay for Rapid AAV Genome Detection

  2022cites this paper
• Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Briefing Document- FDA

  2021cites this paper
• Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing

  2021cites this paper
• Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing

  2021cites this paper
• Adeno-Associated Virus Vector Mobilization, Risk Versus Reality

  2020cites this paper
• Wild type AAV, recombinant AAV, and Adenovirus super infection impact on AAV vector mobilization

  2020cites this paper
• Optimization of the quality by design approach for gene therapy products: a case study for adeno-associated viral vectors.

  2020cites this paper
• Nanopore sequencing of native adeno-associated virus (AAV) single-stranded DNA using a transposase-based rapid protocol

  2019cites this paper
• Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9

  2018cites this paper
• TITLE : Functional rescue of dystrophin deficiency in mice caused by frameshift mutations using Campylobacter jejuni

  2018cites this paper
• Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities

  2017cites this paper
• Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities.

  2017cites this paper
• Molecular design for recombinant adeno-associated virus (rAAV) vector production

  2017influential citation
• Lentiviral vector packaging cell line development using genome editing to target optimal loci discovered by high throughput DNA barcoding

  2017cites this paper
• Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing

  2015cites this paper
• smooth muscle cells in vivo Adeno-associated virus vector transduction of vascular

  2015cites this paper
• Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment

  2014cites this paper
• Construction and optimization of novel recombinant Adeno-Associated Virus rAAV2/5 for targeting microglia to regulate immune responses during neuroinflammation

  2014cites this paper
• Biosafety of recombinant adeno-associated virus vectors.

  2014cites this paper
• Adeno-Associated Virus-Based Vectors

  2014cites this paper
• A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy

  2013cites this paper
• Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production

  2013cites this paper
• Gene Delivery Using Viral Vectors

  2011cites this paper
• Systemic Elimination of de novo Capsid Protein Synthesis from Replication-Competent AAV Contamination in the Liver

  2011cites this paper
• Good Manufacturing Practice Production of Self-Complementary Serotype 8 Adeno-Associated Viral Vector for a Hemophilia B Clinical Trial

  2011cites this paper
• Vector characterization methods for quality control testing of recombinant adeno-associated viruses.

  2011cites this paper
• Recombination in Eukaryotic Single Stranded DNA Viruses

  2011cites this paper
• Viral Vectors for Gene Therapy

  2011cites this paper
• Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases.

  2011cites this paper
• Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production

  2010cites this paper
• Production, purification and characterization of adeno-associated vectors.

  2010cites this paper
• Manufacturing and regulatory strategies for clinical AAV2-hRPE65.

  2010cites this paper
• [Cellular immunotoxicity of rAAV gene medicine and possible solutions].

  2010cites this paper
• Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

  2009cites this paper
• Manufacturing recombinant adeno-associated viral vectors from producer cell clones.

  2009cites this paper
• An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes

  2009cites this paper
• Transient transfection methods for clinical adeno-associated viral vector production.

  2009influential citation
• Improved Splicing of Adeno-Associated Viral (AAV) Capsid Protein-Supplying Pre-mRNAs Leads to Increased Recombinant AAV Vector Production

  2008cites this paper
• Manufacturing and characterizing AAV-based vectors for use in clinical studies

  2008cites this paper
• Within-Host Genetic Diversity of Endemic and Emerging Parvoviruses of Dogs and Cats

  2008cites this paper
• Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production.

  2008cites this paper
• Protein processing strategies by adeno-associated virus type 5 (AAV5) and the effects of the adenovirus E4orf6/E1b-55k/Cullin 5 E3 ubiquitin ligase complex on AAV protein stability

  2008cites this paper
• Evolution and Variation of the Parvoviruses

  2008cites this paper
• Comparative analysis reveals frequent recombination in the parvoviruses.

  2007cites this paper
• Scalable production of adeno‐associated virus type 2 vectors via suspension transfection

  2006influential citation
• Production of research and clinical‐grade recombinant adeno‐associated virus vectors

  2005cites this paper
• A CMV‐actin‐globin hybrid promoter improves adeno‐associated viral vector gene expression in the arterial wall in vivo

  2005cites this paper
• Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production.

  2005influential citation
• Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery.

  2005cites this paper
• Current issues in adeno-associated viral vector production

  2005cites this paper
• Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectors

  2004cites this paper
• The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production.

  2004cites this paper
• Side effects of suicide gene therapy.

  2004cites this paper
• Adeno-associated viral vectors.

  2003cites this paper
• Adeno-associated Virus and AAV Vectors for Gene Delivery

  2003cites this paper
• Evaluation of risks related to the use of adeno-associated virus-based vectors.

  2003cites this paper
• A method for helper virus-free production of adeno-associated virus vectors.

  2003cites this paper
• Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles

  2003cites this paper
• Construction of adeno-associated virus packaging plasmids and cells that directly select for AAV helper functions.

  2003cites this paper
• Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector.

  2003cites this paper
• Virus vectors for use in the central nervous system: adeno-associated viral vectors

  2003cites this paper
• Gene Delivery Technology: Adeno- Associated Virus

  2003cites this paper
• In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer

  2002cites this paper
• Recombinant adeno-associated viral vector production using stable packaging and producer cell lines.

  2002cites this paper
• Recombinant adeno-associated virus vector design and gene expression in the mammalian brain.

  2002cites this paper
• A new packaging cell line for SV40 vectors that eliminates the generation of T-antigen-positive, replication-competent recombinants.

  2002cites this paper
• Autonomous parvovirus vectors.

  2002cites this paper
• Recent advances in recombinant adeno-associated virus vector production.

  2002cites this paper
• A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination

  2001cites this paper
• Viral Vectors for Gene Therapy

  2001cites this paper
• Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV

  2000cites this paper
• CHAPTER 30 – GENE-BASED THERAPEUTICS

  2000cites this paper
• Production of recombinant adeno-associated virus.

  2000cites this paper
• Adeno-associated virus vectors: activity and applications in the CNS.

  2000cites this paper
• Adeno-associated viruses as gene transfer vehicles.

  2000cites this paper
• Recombination within the nonstructural genes of the parvovirus minute virus of mice (MVM) generates functional levels of wild-type NS1, which can be detected in the absence of selective pressure following transfection of nonreplicating plasmids.

  2000cites this paper
• Cell Engineering

  2000cites this paper
• Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6.

  2000cites this paper
• Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review).

  2000cites this paper
• Adeno-associated virus expresses transgenes in hair follicles and epidermis.

  2000cites this paper
• Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo.

  2000cites this paper
• Adeno-Associated Virus: A Promising Tool for Gene Delivery

  2000cites this paper
• High-Titer, Wild-Type Free Recombinant Adeno-Associated Virus Vector Production Using Intron-Containing Helper Plasmids

  2000cites this paper